AU Patent

AU2023208222A1 — Methods of treatment for cystic fibrosis

Assigned to Vertex Pharmaceuticals Inc · Expires 2023-08-17 · 3y expired

What this patent protects

Compound I of the formula N F3 C N \\ N N H 0 0 N N N and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis. 152

USPTO Abstract

Compound I of the formula N F3 C N \\ N N H 0 0 N N N and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis. 152

Drugs covered by this patent

Patent Metadata

Patent number: AU2023208222A1
Jurisdiction: AU
Classification: —
Expires: 2023-08-17
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.